Portfolio Lab

Neogenomics Inc

  • Stock
  • Ticker NEO
  • ISIN US64049M2098
  • Nasdaq

Industrials · Business services · USA

$14.82 −1.79%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Neogenomics Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

NEOGlobal equities (VT)

$10,000 grew to $16,250. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −91.9% in 07/2025, measured from the peak in 02/2021. The old peak has not been reached again yet.

1-year return
+39.8%
5-year return p.a.
−18.0%
10-year return p.a.
+5.0%
Volatility p.a.
62.3%
Largest decline
−91.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue172168181188190187202209
Gross profit7773778083819297
Operating income-18-28-48-27-13-18-9.8-7.9
EBITDA-8.6-18-38-18-4.7-9.5-1.20.6
Net income-15-26-45-27-9.9-172.2-7.5
Balance sheet
Total assets1,6381,6011,3941,3751,3601,3471,3521,377
Liabilities736713540536523518567576
Equity902888854838837829786801
Cash367346155164160146146139
Long-term debt340–––342–374375
Cash flow
Operating cash flow9.8-25208.91.3-8.120-8.9
Capital expenditure-12-4.5-6.3-8.3-7.9-5.0-8.2-12
Free cash flow-1.8-30140.6-6.5-1312-21

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +132.0%, weakest 2022 at −72.9%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
28 Oct 2026–
28 Jul 2026–
28 Apr 2026–
17 Feb 2026–
28 Oct 2025–
29 Jul 2025–
29 Apr 2025–
18 Feb 2025–
5 Nov 2024–
30 Jul 2024–
30 Apr 2024–
20 Feb 2024–

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.7bn
Market cap in trading currency
$1.92bn
Enterprise value
$2.15bn
P/E
–
P/S
2.43
P/B
2.40
EV/Sales
2.73
EV/EBITDA
–
Earnings yield
–
FCF yield
-1.5%

Results (last four quarters)

Revenue
$788m
Gross profit
$353m
EBITDA
−$14.7m
Net income
−$32.3m
Earnings per share
–
Revenue per share
$6.09
Revenue growth
+11.4%
Earnings growth
–

Profitability

Gross margin
44.8%
Operating margin
-6.3%
Net margin
-4.1%
Return on equity
-3.9%
Return on assets
-2.3%

Balance sheet and cash flow

Cash
$139m
Cash per share
$1.08
Financial debt
$375m
Debt/equity %
47
Current ratio
3.53
Book value per share
$6.19
Operating cash flow
$4.28m
Free cash flow
−$28.6m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
129m
Volume
1.18m
Avg. volume 3 months
1.99m
Relative volume
0.6

Price and technicals

Price
$14.82
1 day
−1.8%
52-week high
$19.91
52-week low
$7.19
Distance to 52-week high
−25.6%
Distance to 52-week low
+106.1%
Distance to 50-day line
−14.4%
Distance to 200-day line
+13.4%
RSI (14)
34
Volatility 1M
44.7%

Performance

1 week
−7.5%
1 month
−9.6%
3 months
−9.7%
6 months
+60.6%
YTD
+26.0%
1 year
+44.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has NEO performed since 11/2016?

$10,000 grew to $16,250 by 20 Nov 2026, which is +5.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is NEO?

Volatility was 62.3% per year, measured on monthly returns. The largest decline from a peak was −91.9%, with the low in 07/2025.

How does NEO compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, NEO returned +5.0% at 62.3%. The correlation of monthly returns was 0.33; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Neogenomics Inc (NEO): Return and risk | Portfolio Lab